SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board: 
Last Post: 5/27/2017 10:00:13 PM - Followers: 834 - Board type: Free - Posts Today: 54

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

 
Elite’s website can be found by going to http://www.elitepharma.com


How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.
 


 

Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79416&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78453&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78262&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77581&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77479&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0


More information can be found by going to Elite’s investor section:  http://ir.elitepharma.com/press_releases
Highlights From Last Quarter:
 
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
 
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
 
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.
 

Financials:
 
 
 

Products:
 
http://www.elitepharma.com/products/

Leadership:

President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.


Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: dianne@elitepharma.com

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755
 


Miscellaneous Links:

SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov: https://www.clinicaltrials.gov/




 


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.

               



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP
Current Price
Volume:
Bid Ask Day's Range
ELTP News: Current Report Filing (8-k) 05/22/2017 05:11:01 PM
ELTP News: Small Company Offering and Sale of Securities Without Registration (d) 05/10/2017 05:24:00 PM
ELTP News: Securities Registration Statement (simplified Form) (s-3) 05/10/2017 05:04:05 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 05/03/2017 06:19:02 PM
ELTP News: Current Report Filing (8-k) 05/02/2017 10:51:44 AM
PostSubject
#253565  Sticky Note Depends on your definition of "true dilution" WeeZuhl 05/03/17 02:03:28 PM
#247416  Sticky Note HERE is WHAT long term investors need to UNDERSTAND!!! Couch 03/21/17 06:12:24 PM
#236265  Sticky Note Elite Pharma: The company of firsts: namtae 12/14/16 12:32:00 PM
#234937  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE Couch 11/30/16 03:04:07 PM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#258578   Lasers, my understanding is that Camargo is the elichen 05/27/17 10:00:13 PM
#258577   Sure K just more BS that goes unsupported. Couch 05/27/17 09:29:38 PM
#258576   Things are looking worse and worse for Elite Couch 05/27/17 09:22:38 PM
#258575   That's my point. It's rediculus to turn the vanwes1 05/27/17 08:33:21 PM
#258574   Gee, sounds like the people at Elite really namtae 05/27/17 07:51:41 PM
#258573   There is no our management can't get their Chasing 05/27/17 07:45:22 PM
#258571   The FDA is not responsible for designing drug vanwes1 05/27/17 04:55:34 PM
#258570   Total nonsense. FDA does not get involved in dr_lowenstein 05/27/17 04:15:28 PM
#258569   Either way $ELTP FDA Tmax Trial data results lasers 05/27/17 04:11:32 PM
#258568   Not just BP namtae 05/27/17 03:33:12 PM
#258567   Pray! YJ4LIFE 05/27/17 03:28:56 PM
#258566   One SMALL problem with that BS is that John_Langston 05/27/17 03:23:05 PM
#258565   With the Govt. (FDA) about too come down catty 05/27/17 03:22:08 PM
#258564   the answer is NO dr_lowenstein 05/27/17 03:18:03 PM
#258563   YJ4: this should be your biggest bad. catty 05/27/17 03:16:08 PM
#258562   lasers: I was involved in 2009 with rocioyogi 05/27/17 02:51:45 PM
#258561   I'm very distraught- have invested all my savings jtf3 05/27/17 02:31:56 PM
#258560   GEE and here the BS about a negative Couch 05/27/17 02:13:29 PM
#258558   yeah he thought he might get away with dr_lowenstein 05/27/17 12:45:52 PM
#258557   ah thanks for that, I forgot about the dr_lowenstein 05/27/17 12:35:14 PM
#258556   Didnt you know Elite has special privileges? namtae 05/27/17 12:28:12 PM
#258555   That is correct dr_lowenstein 05/27/17 12:26:00 PM
#258554   that is pure nonsense, there are no "fda dr_lowenstein 05/27/17 12:19:37 PM
#258553   It is very common for a BE/Tmax trial dr_lowenstein 05/27/17 12:18:28 PM
#258552   that is a very plausible explanation, thanks dr_lowenstein 05/27/17 12:14:22 PM
#258551   Good thing it can't go down on Monday! jtf3 05/27/17 11:17:30 AM
#258550   Ok dude jtf3 05/27/17 11:16:39 AM
#258546   Sorry, but back to the point. The FDA namtae 05/27/17 10:17:01 AM
#258545   Yes Indeed FDA regulators decide those that qualify lasers 05/27/17 09:50:52 AM
#258544   That's hilarious I mean I heard of stretching stockboy 05/27/17 09:44:39 AM
#258543   Wow what a load of horse manure that stockboy 05/27/17 09:43:26 AM
#258542   We see how Eugene the legend is really stockboy 05/27/17 09:40:47 AM
#258541   Just join Clay Trader that group made bank stockboy 05/27/17 09:36:14 AM
#258539   LMAO!! The FDA does the recruitment namtae 05/27/17 09:18:39 AM
#258538   It is vital for everyone to understand that lasers 05/27/17 08:47:00 AM
#258537   I'm a millionaire in 5-6 weeks. aELmTPa 05/27/17 08:14:25 AM
#258536   $ELTP is continuing with SequestOx-II (reformulated SequestOx™ ) lasers 05/27/17 07:38:26 AM
#258535   Reformulated SequestOx™ The Holy Grail will be the NASDAQ2020 05/27/17 07:29:50 AM
#258534   13 Pathways to DollarLand NASDAQ2020 05/27/17 07:17:02 AM
#258533   The FDA told Elite it was okay with Couch 05/27/17 06:12:48 AM
#258532   LMAO WOW!!!! An OTC stock good for trading. Couch 05/27/17 06:01:37 AM
#258531   You have to compare MARKET CAP not PPS virelle 05/27/17 05:22:08 AM
#258530   Probably was hoping the FDA would be okay richierichstl 05/27/17 03:03:02 AM
#258528   That would be an incorrect guess. NEXT! Jimmy Joe 05/27/17 02:31:45 AM
#258527   Yes holiday on Monday... YJ4LIFE 05/27/17 01:31:12 AM
#258526   My bad. YJ4LIFE 05/27/17 01:30:51 AM
#258525   Well at least not having a position you stockboy 05/27/17 12:49:21 AM
#258523   Yes and time will tell who was reasonable Bluesummers 05/26/17 08:59:04 PM
#258522   Thanks, I've always been open minded about BS Couch 05/26/17 08:55:44 PM
#258521   Always a pleasure to exchange differing ideas and namtae 05/26/17 08:41:05 PM
PostSubject